PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Dronedarone and Ezetimibe/Simvastatin Interaction

Drug interaction information between Dronedarone and Ezetimibe/Simvastatin.

Dronedarone and Ezetimibe/Simvastatin have a documented major interaction in FDA labeling.

FDA drug labeling documents a major-severity interaction between Dronedarone and Ezetimibe/Simvastatin. Major interactions are generally avoided, moderate ones may need monitoring or a dose adjustment, and minor ones are usually low-risk. This page shows the documented mechanism and guidance. Label-documented interactions are not a complete safety review, so always confirm your own medications with a pharmacist or doctor. Educational information, not medical advice.

Drug A

Dronedarone

Class III Antiarrhythmic

Drug B

Ezetimibe/Simvastatin

Cholesterol Absorption Inhibitor / Statin Combination

How They Interact

Dronedarone interferes with how your body breaks down simvastatin, leading to higher drug levels and a greater risk of muscle damage.

What To Do

Do not take more than 10/10 mg of VYTORIN daily while you are taking dronedarone.

FDA Label Information

Amiodarone, Dronedarone, Ranolazine, or Calcium Channel Blockers Clinical Impact: The risk of myopathy and rhabdomyolysis is increased by concomitant use of amiodarone, dronedarone, ranolazine, or calcium channel blockers with VYTORIN. Intervention: For patients taking verapamil, diltiazem, or dronedarone, do not exceed VYTORIN 10/10 mg daily.

Frequently Asked Questions

Can I take Dronedarone and Ezetimibe/Simvastatin together?

This is a major interaction. Do not take more than 10/10 mg of VYTORIN daily while you are taking dronedarone.

How serious is the interaction between Dronedarone and Ezetimibe/Simvastatin?

This interaction is classified as "major" severity by the FDA. Major interactions may be life-threatening or cause serious side effects.

Why do Dronedarone and Ezetimibe/Simvastatin interact?

Dronedarone interferes with how your body breaks down simvastatin, leading to higher drug levels and a greater risk of muscle damage.

Understanding the Dronedarone and Ezetimibe/Simvastatin Interaction

FDA-approved prescribing information for these two drugs flags their combination as a major-severity interaction. Dronedarone belongs to the Class III Antiarrhythmic class and Ezetimibe/Simvastatin belongs to the Cholesterol Absorption Inhibitor / Statin Combination class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Dronedarone interferes with how your body breaks down simvastatin, leading to higher drug levels and a greater risk of muscle damage. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Dronedarone has 22 total documented interactions on file in this dataset, and Ezetimibe/Simvastatin has 23. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Do not take more than 10/10 mg of VYTORIN daily while you are taking dronedarone. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Dronedarone or Ezetimibe/Simvastatin based on a web page, speak with your prescriber or pharmacist before making any change.

Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. Always consult your healthcare provider about drug interactions.